To the Editor:—
The special article entitled "Medical Patents" published in the November 6 issue of The Journal implies that the Scarlet Fever Committee has interfered with research through its methods of administering the patent on scarlet fever toxin and scarlet fever antitoxin. In reply to this implication and the author's statement that such effect is probably due to the personnel of the committee, it should be stated that application for a patent was not made until after receipt of the following letter from the director of the National Institute of Health, and after consultation with the Council on Pharmacy and Chemistry of the American Medical Association, which concurred in the advice given in this letter.TREASURY DEPARTMENT United States Public Health Service Washington, D. C. November 12, 1924.Dr. Geo. F. Dick, c/o John McCormick Institute for Infectious Diseases, # 637 South Wood Street, Chicago, Illinois.
Dear Doctor Dick:—